Deutsche Bank
XLO icon

Deutsche Bank’s Xilio Therapeutics XLO Stock Holding History

Deutsche Bank’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-288
Closed -$28K – 4350
2022
Q1 		$28K Sell
288
-34
-11% -$5.38K ﹤0.01% 3994
2021
Q4 		$72K Buy
+322
New +$76.8K ﹤0.01% 3842

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Deutsche Bank's XLO Position: Q2 2022 in Review

Deutsche Bank sold out of Xilio Therapeutics (XLO) in Q2 2022, closing a stake of 288 shares — an estimated $28K sold.

Deutsche Bank first reported a position in XLO in Q4 2021 and held it in 2 quarters. The position peaked at $72K in Q4 2021. 32 funds tracked by Wall St. Rank hold XLO as of Q2 2022.

  • Deutsche Bank reported no remaining Xilio Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Deutsche Bank sold 288 Xilio Therapeutics shares in Q2 2022, an estimated $28K.
  • Deutsche Bank first reported a position in Xilio Therapeutics in Q4 2021 and held it in 2 quarters.
  • Deutsche Bank's Xilio Therapeutics position peaked at $72K in Q4 2021.
  • 32 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2022.

Based on Deutsche Bank's 13F filing for Q2 2022, filed 11 Aug 2022.